Skip to main content
SpringerLink
Log in
Book cover

Prostate Cancer pp 33–63Cite as

The Prevention of Prostate Cancer

  • Chapter

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 175))

Abstract

From our better understanding of the natural history of prostate cancer, it is not unreasonable to believe that the disease is preventable. Prostate cancer has become a major healthcare problem worldwide, as life expectancy increases. Moreover, the cancer is slow growing, with a period of about 20–25 years from initiation to the stage when the clinically detectable phenotype can be identified. This review provides a simple overview of the endocrinology of prostate cancer and discusses some of the pharmaceutical agents that have been or are being tested to restrain, possibly arrest, the progression of this slowly growing cancer. Also discussed are many of the dietary factors that may influence the molecular or endocrine events implicated in its development. Dietary factors are considered responsible for the geographical differences in prostate cancer incidence and mortality. Since about 50% of all men worldwide, from both East and West, show evidence of microscopic cancer by 50 years of age, growth restraint would appear to be the pragmatic option to the possibility of preventing initiation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Huggins C (1963) Introduction. In: Vollmer EP, Kauffmann G (eds) Biology of the prostate and related tissues, monograph 12. National Cancer Institute, U.S. Department of Health Education and Welfare, pp xi–xii

    Google Scholar 

  2. Parkin DM, Whelan SI, Ferlay J, Raymond L, Young J (eds) (1997) Cancer incidence in five continents, vol VII. Scientific Publications

    Google Scholar 

  3. Adlercreutz H (1990) Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 50:3–23

    Google Scholar 

  4. Griffiths K, Adlercreutz H, Boyle P, Denis L, Nicholson RI, Morton MS (1996) Nutrition and cancer. Isis Medical Media, Oxford

    Google Scholar 

  5. Griffiths K, Cockett ATK, Coffey D, Di Sant’Agnese A, Krieg M, Lee C, McKeehan W, Neal DE, Partin A, Schalken J (1997) Regulation of prostatic growth. In: Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy G, Yoshida O (eds) The 4th International Consultation on BPH. SCI, Paris, pp 85–128

    Google Scholar 

  6. Lee C, Cockett A, Cussenot O, Griffiths K, Isaacs W, Scalken J (2001) Regulation of prostate growth. In: Chatelain C, Denis L, Foo KT, Khoury S, Mc-Connell J (eds) Benign prostatic hyperplasia, the 5th International Consultation on BPH. Health Publications, Paris, pp 81–106

    Google Scholar 

  7. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A 98:6330–6335

    Article  CAS  PubMed  Google Scholar 

  8. Bartsch G, Klocker H, Ackermann R, Di Sant’Agnese PA, Cussenot O, Lee C, Narayan P, Nelson J, Salgaller ML, Schulman CC, Steiner MS (2000) Translational research areas and new treatment modalities. In: Murphy G, et al (eds) Second International Consultation on Prostate Cancer. Health Publications, Paris, pp 59–136

    Google Scholar 

  9. Griffiths K, Denis LJ, Turkes A (2002) Oestrogens, phyto-oestrogens and the pathogenesis of prostatic disease. Martin Dunitz, London

    Google Scholar 

  10. World Cancer Research Fund (1997) Food, nutrition and the prevention of cancer: a global perspective. Banta Book Group, Manasha

    Google Scholar 

  11. De Koning HJ, Auvinen A, Berenguer Sanchez A, et al (2002) Large scale randomised prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer and the Prostate, lung, Colorectal and Ovary Cancer Trial. Int J Cancer 97:237–244

    Article  PubMed  CAS  Google Scholar 

  12. Griffiths K, The Internatonal Prostate Health Council Study Group (2000) Estrogens and prostatic disease (review). Prostate 45:87–100

    Article  CAS  PubMed  Google Scholar 

  13. Rotkin ID (1976) Epidemiology of benign prostatic hypertrophy: Review and speculations. In: J.T. Grayhack, J.D. Wilson & M.J. Saherbenske (eds) Benign prostatic hyperplasia. DHEW Publications, pp 105–117

    Google Scholar 

  14. Rotkin ID (1980) Epidemiologic clues to increased risk of prostae cancer. In: Spring-Mills E, Hafez ESE (eds) Male accessory sex glands: biology and pathology. Elsevier/North-Holland Medical Press, Amsterdam, pp 289–311

    Google Scholar 

  15. Chang WY, Birch L, Woodham C, Gold LI, Prins GS (1999) Neonatal estrogen exposure alters the transforming growth factor-beta signaling system in the developing rat prostate and blocks the transient p21 (cip1/waf1) expression associated with epithelial differentiation. Endocrinology 140:2801–2813

    Article  CAS  PubMed  Google Scholar 

  16. Wang YZ, Hayward SW, Cao M, Young P, Cardiff R, Cunha GR (2001) Role of estrogen signalling in prostatic hormonal carcinogenesis. J Urol (Suppl) 165:132–133

    Google Scholar 

  17. Risbridger G, Wang H, Frydenberg M, Cunha GR (2001) The metaplastic effects of estrogen on prostate epithelium proliferation of cells with basal cell phenotype. Endocrinology 142:2443–2450

    Article  CAS  PubMed  Google Scholar 

  18. Cunha GR, Hayward SW, Wang YZ, Ricke WA (2003) Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 107:1–10

    Article  CAS  PubMed  Google Scholar 

  19. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479

    CAS  PubMed  Google Scholar 

  20. McNeal JE (1984) Anatomy of the prostate and morphogenesis of BPH. In: Kimball FA, Buhl AE, Carter DB (eds) New approaches to the study of benign prostatic hyperplasia. Alan R Liss, New York, pp 27–53

    Google Scholar 

  21. Sakr WA (1999) Prostatic intraepithelial neoplasia: a marker for high-risk groups and a potential target for chemoprevention. Eur Urol 35:474–478

    Article  CAS  PubMed  Google Scholar 

  22. Sakr WA, Partin AW (2001) Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia (Review). Urology 57(Suppl):115–120

    Article  CAS  PubMed  Google Scholar 

  23. Bostwick DG, Pacelli A, Lopez-Beltran A (1996) Molecular biology of prostatic intraepithelial hyperplasia. Prostate 29:117–134

    Article  CAS  PubMed  Google Scholar 

  24. De Marzo AM, Nelson WG, Isaacs WB, Epstein JI (2003) Pathological and molecular aspects of prostate cancer. Lancet 361:955–964

    Article  CAS  Google Scholar 

  25. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992

    PubMed  Google Scholar 

  26. Naslund M, Coffey DS (1986) The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. J Urol 136:1136–1140

    CAS  PubMed  Google Scholar 

  27. Coffey DS (2001) Similarities of prostate and breast cancer: evolution, diet and estrogens. Urology 57Suppl 57:31–38

    Article  CAS  PubMed  Google Scholar 

  28. Putzi MJ, De Marzo AM (2000) Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56:828–832

    Article  CAS  PubMed  Google Scholar 

  29. Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, Nelson CP, Groopman JD, Kensler TW (2001) Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 952:135–144

    Article  CAS  PubMed  Google Scholar 

  30. Prezioso D, et al (2005) Oestrogens and diseases of the prostate gland (In press)

    Google Scholar 

  31. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM (1991) Brit. Cancer 63:963–966

    CAS  Google Scholar 

  32. Watanaba S (1993) Large-scale, populationbased prospective studies in Japan. Eur J Cancer 29A:2305–2314

    Article  Google Scholar 

  33. Hsing AW, Tsao I, Devesa SS (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85:60–67

    Article  CAS  PubMed  Google Scholar 

  34. Thompson IM, Albanes D, Griffiths K et al (2003) Chemoprevention on prostate cancer. In: Denis L, Khoury S, Chatelain C, et al (eds) Third International Consultation on Prostate Cancer: New treatment modalities. Health Publications

    Google Scholar 

  35. Gann PH, Akaza H, Habib F, Kirby R, Mendoza AV, Thompson IM, Van Poppel H (2006) Prostate cancer prevention. In: Proceedings of the Sixth International Consultation on Prostate Cancer; New Development in Prostate Cancer, Paris, 24–27 June 2005. pp 247–274

    Google Scholar 

  36. Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R (2004) Prostate cancer chemoprevention agent development: the national cancer institute, division of cancer prevention portfolio. J Urol 171:S68–S75

    Article  PubMed  Google Scholar 

  37. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TN (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP-1 sites. Science 277:1508–1510

    Article  CAS  PubMed  Google Scholar 

  38. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H (2004) Androgen receptor regulation by physiological concentratins of the isoflavnoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor β. Eur Urol 45:245–251

    Article  CAS  PubMed  Google Scholar 

  39. Matthews J, Gustafsson JA (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta (Review). Mol Interv 3:281–292

    Article  CAS  PubMed  Google Scholar 

  40. Price KR, Fenwick GR (1985) Naturally occurring oestrogens in food-a review. Food Addit Contam 2:73–106

    CAS  PubMed  Google Scholar 

  41. Hellendoorn EW (1976) Beneficial physiologic action of beans. J Am Diet Assoc 69:248–253

    CAS  PubMed  Google Scholar 

  42. Adlercreutz H, Fotsis T, Lampe J, Wahala K, Makela T, Brunow G, Hase T (1993) Quantative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas chromatography-mass spectrometry. Scand J Clin Lab Invest 53:(Suppl) 5–18

    CAS  Google Scholar 

  43. Morton MS, Chan PS, Cheng C, Blacklock N, Matos-Ferreira A, Abranches-Monteiro L, Lloyd S, Griffiths K (1997) Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong and the United Kingdom. Prostate 32:122–128

    Article  CAS  PubMed  Google Scholar 

  44. Pumford SL, Morton MS, Turkes A, Griffiths K (2002) Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry. Ann Clin Biochem 39:281–292

    Article  CAS  PubMed  Google Scholar 

  45. Kuhnau J (1976) The flavonoids. A class of semiessential food components: their role in human nutrition. World Rev Nutr Diet 24:117–191

    CAS  PubMed  Google Scholar 

  46. Waladkhani A, Clemens MR (1998) Effect of dietary phytochemicals on cancer development (Review). Int J Mol Med 1:747–753

    CAS  PubMed  Google Scholar 

  47. Nutrient Data Laboratory (2003) USDA database for the flavonoid content of selected foods. U.S. Department of Agriculture, pp 1–77

    Google Scholar 

  48. Rao CV, Rivensen A, Simi B, Reddy BS (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring phenolic compound. Cancer Res 55:259–266

    CAS  PubMed  Google Scholar 

  49. Miksicek RJ (1995) Estrogenic flavonoids: structuralrequirements for biological activity. Proc Soc Exp Biol Med 208:440–450

    Google Scholar 

  50. Galati G, O’Brien JP (2004) Potential toxicity off flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med 37:287–303

    Article  CAS  PubMed  Google Scholar 

  51. Wolf CR (2001) Chemoprevention: increased potential to bear fruit. Proc Natl Acad Sci U S A 98:2941–2943

    Article  CAS  PubMed  Google Scholar 

  52. Shamberger RJ, Frost DV (1969) Possible protective effect of selenium against human cancer. Can Med Assoc J 100:682

    CAS  PubMed  Google Scholar 

  53. Comstock GW, Bush TL, Helzlsouer K (1992) Serum retinol, beta-carotene, vitamin E and selenium as related to subsequent cancer specific sites. Am J Epidemiol 135:115–121

    CAS  PubMed  Google Scholar 

  54. Combs GF (1997) Antioxidants and disease prevention. In: Garewal HS (ed) Selenium and cancer prevention. pp 97–112

    Google Scholar 

  55. Medina D, Morrison DG (1988) Current ideas on selenium as a chemopreventive agent. Pathol Immunopathol Res 7:187–199

    CAS  PubMed  Google Scholar 

  56. Menter DG, Sabichi AL, Lippman SM (2000) Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9:1171–1182

    CAS  PubMed  Google Scholar 

  57. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E (1998) Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90:1219–1224

    Article  CAS  PubMed  Google Scholar 

  58. Clark LC, Dalkin B, Krongrad A, Combs GF, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81:730–734

    CAS  PubMed  Google Scholar 

  59. Rayman MP (1997) Dietary selenium: time to act. Br Med J 314:387–388

    CAS  Google Scholar 

  60. Howe GR (1990) Dietary fat and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst 82:561–569

    Article  CAS  PubMed  Google Scholar 

  61. Garland M, Willett WC, Manson JE, Hunter DJ (1993) Antioxidant micronutrients and breast cancer. J Am Coll Nutr 12:400–411

    CAS  PubMed  Google Scholar 

  62. Hunter DJ, Manson J, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE, Willett WC (1993) A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 329:234–240

    Article  CAS  PubMed  Google Scholar 

  63. Boyle P, Maisonneuve P (1996) Diet, In: J. Waxman (ed) Molecular endocrinology of cancer. Cambridge University Press, pp 216–268

    Google Scholar 

  64. Boyle P, Maisonneuve P, Evstififeeva T, Alexander FE (1995) What is the significance of trends in prostate cancer? In: Murphy GP, Khoury S, Chatelain C, Denis L (eds) Fourth International Symposium on Recent Advances in Urological Cancer, Diagnosis and Treatment. SCI, Paris, pp 51–65

    Google Scholar 

  65. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM, Palmgren J (1995) Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-carotene Cancer Prevention Study. Am J Clin Nutr 62(Suppl):1427S–1430S

    CAS  PubMed  Google Scholar 

  66. Agarwal S, Roa AV (2000) Tomato, lycopene and its role in human health and chronic diseases. CMAJ 163:739–744

    CAS  PubMed  Google Scholar 

  67. Sies H, Stahl W (1995) Vitamins E and C, β-carotene and other carotenoids as antioxidants. Am J Clin Nutr 62(Suppl 6):1315S–1321S

    CAS  PubMed  Google Scholar 

  68. Kohimeier L, Kark JD, Gomez-Gracia E, Martin BC, Steek SE, Kardinaal AF, Ringstad J, Thamm M, Masaev V, Riemersma R, Martin-Moreno JM, Huttunen JK, Kok FJ (1997) Lycopene and myocardial infarction risk in the EURAMIC Study. Am J Epidemiol 146:618–626

    Google Scholar 

  69. Kotake-Nara E, Kushiro M, Zhang H, Sugawara T, Mayashita K, Nagao A (2001) Carotenoids affect the proliferation of human prostate cancer cells. J Nutr 131:3303–3306

    CAS  PubMed  Google Scholar 

  70. Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y (2000) Lycopene interferes with cell cycle progression and insulin-like growth factor I signalling in mammary cancer cells. Nutr Cancer 36:101–111

    Article  CAS  PubMed  Google Scholar 

  71. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW, Clinton SK (2003) Prostate carcinogenesis in N-methyl_N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 95:1578–1586

    CAS  PubMed  Google Scholar 

  72. Giovannucci E, Rimm ED, Liu Y, Stampfer MJ, Willett WC (2002) A prospective study of tomato products, lycopene and prostate cancer. J Natl Cancer Inst 94:391–398

    CAS  PubMed  Google Scholar 

  73. Moon RC, Mehta RG (1990) Chemoprevention of mammary cancer by retinoids. Basic Life Sci 52:213–224

    CAS  PubMed  Google Scholar 

  74. Olsen JA (1989) Provitamin A function of carotenoids: the conversion of ?-carotene into vitamin A. J Nutr 119:105–108

    Google Scholar 

  75. Parker RS (1989) Carotenoids in human blood and tissues. J Nutr 119:101–104

    CAS  PubMed  Google Scholar 

  76. Hayes RB, Bogdanovicz JF, Schroeder FH, De Bruijn A, Raatgever JW, van der Maas PJ, Oishi K, Yoshida O (1988) Serum retinol and prostatic cancer. Cancer 62:2021–2026

    Article  CAS  PubMed  Google Scholar 

  77. Lasnitski I (1955) The influence of A-hypervitaminosis on the effect of 20-methylcholanthrene on mouse prostate glands in vitro. Br J Cancer 9:434–441

    Google Scholar 

  78. Lasnitski I (1976) Reversal of methylcholanthrene-induced changes in mouse prostates in vitro by retinoic acid and its analogues. Br J Cancer 34:239–248

    Google Scholar 

  79. Petkovich M, Brand NJ, Krust A, Chambon P (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444–450

    Article  CAS  PubMed  Google Scholar 

  80. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM (1990) nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345:224–229

    Article  CAS  PubMed  Google Scholar 

  81. Zhang XK, Lehmann J, Hoffmann B, Dawson M, Cameron J, Graupner G, Hermann T, Pfahl M (1992) Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature 358:587–591

    Article  CAS  PubMed  Google Scholar 

  82. Blumberg B, Mangelsdorf DJ, Dyck JA, Bittner DA, Evans RM, De Robertis EM (1992) Multiple retinoid-responsive receptors in a single cell: families of retinoid “X” receptors and retinoic acid receptors in the Xenopus egg. Proc Natl Acad Sci U S A 89:2321–2325

    Article  CAS  PubMed  Google Scholar 

  83. Freedman LP, Arce V, Fernandez RP (1994) DNA sequences that act as high affinity targets for the vitamin D3 receptor in the absence of the retinoid X receptor. Mol Endocrinol 8:265–273

    Article  CAS  PubMed  Google Scholar 

  84. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM (1992) Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signaling. Nature 355:446–449

    Article  CAS  PubMed  Google Scholar 

  85. Graupner G, Zhang XK, Tzukerman M, Wills K, Hermann T, Pfahl M (1991) Thyroid hormone receptors repress estrogen receptor activation of a TRE. Mol Endocrinol 5:365–372

    CAS  PubMed  Google Scholar 

  86. Ptahl M (1993) Nuclear receptor/AP-1 interaction. Endocr Rev 14:651–658

    Article  Google Scholar 

  87. Roberts AB, Sporn MB (1984) Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts AB, Goodman DS (eds) The retinoids. The Academic Press, Orlando, pp 209–286

    Google Scholar 

  88. de The H, Marchio A, Tiollais P, Dejean A (1989) Differential expression and ligand regulation of the retinoic acid receptor α and β genes. EMBO J 8:429–433

    PubMed  Google Scholar 

  89. Dolle P, Ruberte E, Kastner P, Petkovich M, Stoner CM, Gudas LJ, Chambon P (1989) Differential expression of genes encoding α, β and γ retinoic acid receptors and CRABP in the developing limbs of the mouse. Nature 342:702–705

    Article  CAS  PubMed  Google Scholar 

  90. Jones HE, Eaton CL, Barrow D, Dutkowski C, Griffiths K (1997) Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic prostate cell lines. Prostate 30:174–182

    Article  CAS  PubMed  Google Scholar 

  91. Roman SD, Ormandy CJ, Manning DL, Blamey RW, Nicholson RI, Sutherland RL, Clarke CL (1993) Estradiol induction of retinoic acid receptors in human breast. Cancer Res 53:5940–5945

    CAS  PubMed  Google Scholar 

  92. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, Verma IM, Evans RM (1991) Retinoic acid is a negative regulator of AP-1 responsive genes. Proc Natl Acad Sci U S A 88:6092–6096

    Article  CAS  PubMed  Google Scholar 

  93. Yang-Yen HF, Zhang XK, Graupner G, Tzukerman M, Sakamoto B, Karin M, Pfahl M (1991) Antagonism between retinoic acid receptors and AP-1: implication for tumor promotion and inflammation. New Biol 3:1206–1219

    CAS  PubMed  Google Scholar 

  94. Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 10:1307–1311

    CAS  PubMed  Google Scholar 

  95. Corder EH, Guess HA, Hulka B, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N (1993) Vitamin D and prostate cancer: a prediagnostic study with stored data. Cancer Epidemiol Biomarkers Prev 2:467–472

    CAS  PubMed  Google Scholar 

  96. Pike JW (1991) Vitamin D3 receptors: structure and function in transcription. Annu Rev Nutr 11:189–216

    Article  CAS  PubMed  Google Scholar 

  97. Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T (1983) Regulation of terminal differentiation of cultured mouse epidermal cells by 1α,25-dihydroxyvitamin D3. Endocrinology 113:1950–1957

    CAS  PubMed  Google Scholar 

  98. Matsumoto K, Hashimoto K, Nishidi Y, Hashiro M, Yoshikawa K (1990) Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun 166:916–923

    Article  CAS  PubMed  Google Scholar 

  99. Ahonen MH, Tenkanen L, Teppo L, et al (2000) Prostate cancer risk and prediagnostic serun 25-hydroxyvitamin D levels in Finland. Cancer Causes Control 11:847–852

    Article  CAS  PubMed  Google Scholar 

  100. Wynder EL, Mabuchi K, Whitmore WF (1971) Epidemiology of cancer of the prostate. Cancer 28:344–360

    Article  CAS  PubMed  Google Scholar 

  101. Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223

    CAS  Google Scholar 

  102. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974) Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186:1213–1215

    Article  CAS  PubMed  Google Scholar 

  103. Imperato-McGinley J, Peterson RE, Gautier T, Sturla F (1979) Androgens and the evolution of male gender identity among male pseudohermaphrodites with 5-alpha reductase deficiency. N Engl J Med 300:1233–1237

    Article  CAS  PubMed  Google Scholar 

  104. Stoner E (1990) The clinical development of a 5alpha-reductase inhibitor, finasteride. J Steroid Biochem 37:375–384

    Article  CAS  Google Scholar 

  105. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E (1992) Finasteride, an inhibitor of 5alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 74:505–508

    Article  CAS  PubMed  Google Scholar 

  106. Unger JM, Thompson IM, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA (2005) Estimated impact of the prostate cancer prevention trial on population mortality. Cancer 103:1375–1380

    Article  PubMed  Google Scholar 

  107. Thompson IM, Goodman PJ, Tangem CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  CAS  PubMed  Google Scholar 

  108. Raghow S, Hooshdaran MZ, Katiyar S, et al (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62:1370–1376

    CAS  PubMed  Google Scholar 

  109. Risbridger G, Wang H, Young P, et al (2001) Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates the effects of estrogen on prostatic epithelium. Dev Biol 229:432–442

    Article  CAS  PubMed  Google Scholar 

  110. Steiner MS, Boger R, Barnette KG, Mitchell J, Bostwick D, Price D (2005) Evaluation of toremifene in reducing prostate cancer incidence in high risk men. 2005 Prostate Cancer Symposium. Am Soc Clin Oncol, abstr 7

    Google Scholar 

  111. Meikle AW, Smith JR, West DW (1985) Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 6:121–128

    Article  CAS  PubMed  Google Scholar 

  112. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361:859–864

    Article  PubMed  Google Scholar 

  113. Eales RA, Durocher F, Edwards S, et al (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The CRC-British Prostate Group Familial Prostate Cancer Study. Am J Hum Genet 62:653–658

    Article  Google Scholar 

  114. Coetzee GA, Ross RK (1994) Prostate cancer and the androgen receptor. J Natl Cancer Inst 86:872–873

    Article  CAS  PubMed  Google Scholar 

  115. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Hendersen BE, Reichardt JK (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles. Lancet 354:975–978

    Article  CAS  PubMed  Google Scholar 

  116. Culig Z, Klocker H, Bartsch G, Hobisch A (2002) Androgen receptors in prostate cancer. Endocr Relat Cancer 9:155–170

    Article  CAS  PubMed  Google Scholar 

  117. Ross RK (2001) The role of molecular genetics in chemoprevention studies of prostate cancer. In: Miller AB, et al (eds) Biomarkers in cancer prevention. IARC Scientific Publications, Lyon

    Google Scholar 

  118. Lopez-Otin C, Diamandis E (1998) Breast and prostate cancer: an analysis of common epidemiological, genetic and biochemical features. Endocr Rev 19:365–396

    Article  CAS  PubMed  Google Scholar 

  119. Imamov O, Lopatkin NA, Gustafsson JA (2004) Estrogen receptor beta in prostate cancer. N Engl J Med 351:2773–2774

    Article  PubMed  Google Scholar 

  120. Armstrong B, Doll R (1975) Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15:617–631

    Article  CAS  PubMed  Google Scholar 

  121. Riboli E (2001) The european prospective investigation into cancer and nutrition (EPIC). J Nutr 131:170S–175S

    CAS  PubMed  Google Scholar 

  122. Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727

    Article  PubMed  Google Scholar 

  123. Moyad MA (2002) Dietary fat reduction to reduce prostate cancer risk: controlled enthusiasm, learning from breast or other cancers, and the big picture. Urology 59(Suppl 1):51–62

    Article  PubMed  Google Scholar 

  124. Skrabanek P (1994) Invited viewpoints. Eur J Cancer 30A:220–221

    Article  Google Scholar 

  125. Taubes G (2001) The soft science of dietary fat. Science 291:2536–2545

    Article  CAS  PubMed  Google Scholar 

  126. Freedland SJ, Aronson WJ (2004) Examining the relationship between obesity and prostate cancer. Rev Urol 6:73–81

    PubMed  Google Scholar 

  127. Engeland A, Tretli S, Bjorge T (2003) Height, body mass index and prostate cancer: a follow-up of 950,000 Norwegian men. Br J Cancer 89:1237–1242

    Article  CAS  PubMed  Google Scholar 

  128. Giovannucci E, Rimm EB, Liu Y, et al (2003) Body mass index and risk of prostate cancer in U. health professionals. J Natl Cancer Inst 95:1240–1244

    Article  PubMed  Google Scholar 

  129. Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T, Arosenema PJ, Kellis JT, Vickery LE (1993) Inhibition of human aromatase by mammalian lignan and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 44:147–153

    Article  CAS  PubMed  Google Scholar 

  130. Okasha M, McCarron P, McEwen J, Smith GD (2002) Body mass index in young adulthood and cancer mortality: a retrospective cohort study. J Epidemiol Community Health 56:780–784

    Article  CAS  PubMed  Google Scholar 

  131. Kaaks R (2001) Energy balance and cancer: the role of insulin and insulin-like growing factor-I. Proc Nutr Soc 60:91–106

    Article  CAS  PubMed  Google Scholar 

  132. Kaaks R, Lukanova A, Sommersberg B (2000) Plasma androgens, IGF-I and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 3:157–172

    Article  CAS  PubMed  Google Scholar 

  133. Barnard RJ, Aronson WJ, Tymchk CN, Ngo TH (2002) Prostate cancer: another aspect of the insulin-resistance syndrome. Obes Rev 3:303–308

    Article  CAS  PubMed  Google Scholar 

  134. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489

    Article  CAS  PubMed  Google Scholar 

  135. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM (1999) The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59:2203–2209

    CAS  PubMed  Google Scholar 

  136. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens H, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566

    Article  CAS  PubMed  Google Scholar 

  137. Turkes A, Peeling WB, Griffiths K (2000) Serum IGF-1 determination in relation to prostate cancer screening: possible differential diagnosis in relation to PSA assays. Prostate Cancer Prostatic Dis 3:173–175

    Article  CAS  PubMed  Google Scholar 

  138. Allen NE, Key TJ (2001) Plasma insulin-like growth factor-I, insulin-like growth factor binding proteins and prostate cancer risk: a prospective study. J Natl Cancer Inst 93:649–651

    Article  CAS  PubMed  Google Scholar 

  139. Apter D, Vihko R (1983) Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab 57:82–86

    Article  CAS  PubMed  Google Scholar 

  140. Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L, Petros JA, Arnold RS (2005) Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 62:200–207

    Article  CAS  PubMed  Google Scholar 

  141. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB (2001) Cyclooxygenase-2 is upregulated in proliferative inflammatory atrophy of the prostate, but not in prostate cancinoma. Cancer Res 61:8617–8623

    CAS  PubMed  Google Scholar 

  142. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anti-cancer agents: mechanistic, parmacologic and clinical issues. J Natl Cancer Inst 94:252–257

    CAS  PubMed  Google Scholar 

  143. Montano MM, Jaiswal AK, Katzenellenbogan BS (1998) Transcriptional regulation of the human quinone reductase gene by anti-estrogen liganded estrogen receptor-alpha and estrogen receptorbeta. J Biol Chem 273:25443–25449 i

    Article  CAS  PubMed  Google Scholar 

  144. Hedlund TE, Johannes WU, Miller GI (2003) Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54:68–78

    Article  PubMed  CAS  Google Scholar 

  145. Adebamowo CA, Cho E, Sampson L, Katan MB, Spiegelman D, Willett WC, Holmes MD (2005) Dietary flavonols and flavanol-rich foods intake and the risk of breast cancer. Int J Cancer 114:628–633

    Article  CAS  PubMed  Google Scholar 

  146. Ratan HL, Steward WP, Gescher AJ, Mellon JK (2002) Resveratrol: a prostate cancer chemopreventive agent. Urol Oncol 7:223–227

    Article  CAS  PubMed  Google Scholar 

  147. Soleas GJ, Diamandis EP, Goldberg DM (1997) Wine as a biological fluid: history, production and role in disease prevention. J Clin Lab Anal 11:287–313

    Article  CAS  PubMed  Google Scholar 

  148. Shen G, Guo-Zhen L, Zhengxin W (2004) Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 59:214–225

    Article  CAS  Google Scholar 

  149. Scaltriti M, Belloni L, Caporali A, Davalli P, Remondini D, Rizzi F, Astancolle S, Corti A, Bettuzzi S (2005) Molecular classification of green tea catechin-sensitive and-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis 27:1047–1053

    Article  PubMed  Google Scholar 

  150. Mazur WM, Adlercreutz H (1998) Naturally occurring oestrogens in food. Pure Appl Chem 70:1759–1776

    CAS  Google Scholar 

  151. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H (2004) Oral consumption of green tea polyphenols inhibits insulin-like growth factor I-induced signalling in an autochthonous mouse model of prostate cancer. Cancer Res 64:8715–8722

    Article  CAS  PubMed  Google Scholar 

  152. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from one-year proof-of-principle study. Cancer Res 66:1234–1240

    Article  CAS  PubMed  Google Scholar 

  153. Jian L, Xie LP, Lee AH, Binns CW (2004) Protective effect of green tea against prostate cancer: a case-control study in South Eastern China. Int J Cancer 108:130–135

    Article  CAS  PubMed  Google Scholar 

  154. Pezzato E, Sartor L, Dell’Aica I, Dittadi R, Gion M, Bellucco C, Lise M, Garbisa S (2004) Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 112:787–792

    Article  CAS  PubMed  Google Scholar 

  155. Ren F, Zhang S, Mitchell SH, Butler R, Young CYF (2000) Tea polyphenols down-regulate the expression of androgen receptor in LNCaP prostate cancer cells. Oncogene 19:1924–1932

    Article  CAS  PubMed  Google Scholar 

  156. Purohit V (2000) Can alcohol promote the aromatisation of androgens to estrogens? A review. Alcohol 22:123–127

    Article  CAS  PubMed  Google Scholar 

  157. Fahey JW, Zhang Y, Talalay P (1997) Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect agains chemical carcinogens. Proc Natl Acad Sci U S A 94:10367–10372

    Article  CAS  PubMed  Google Scholar 

  158. Fereira CG, Epping M, Kruyt FA, Giaccone G (2002) Apoptosis: target of cancr therapy. Clin Cancer Res 8:2024–2034

    Google Scholar 

  159. Reed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17:2941–2953

    CAS  PubMed  Google Scholar 

  160. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN (1991) Selective inhibition of isoprenylation of 21/26 kDa proteins by the anti-carcinogenic d-limonene and its metabolites. J Biol Chem 266:176–179

    Google Scholar 

  161. Magee T, Marshall C (1999) New insights into the interaction of Ras with plasma membrane. Cell 98:9–12

    Article  CAS  PubMed  Google Scholar 

  162. Miyamoto M, Matsushita Y, Kiyokawa A, Fukuda C, Iijima Y, Sugano M, Akiyama T (1998) Prenylflavonoids: a new class of non-steroidal phytoestrogen. Estrogenic effects of 8-isopentenylnaringenin on bone metabolism. Planta Med 64:516–519

    Article  CAS  PubMed  Google Scholar 

  163. Theriault A, Chao JT, Wang Q, Gapor A, Adeli K (1999) Tocotrienol: a review of its therapeutic potential. Clin Biochem 32:309–319

    Article  CAS  PubMed  Google Scholar 

  164. Bradlow L, Telang NT, Osborn MP (1996) Estrogen metabolites as bioreactive modulators of tumor initiation and promoters. Adv Exp Med Biol 367:285–296

    Google Scholar 

  165. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368:237–239

    Article  CAS  PubMed  Google Scholar 

  166. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (1999) Estrogen receptor expression in prostatic cancer and premalignant prostatic lesions. Am J Pathol 155:641–647

    CAS  PubMed  Google Scholar 

  167. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336

    Article  CAS  PubMed  Google Scholar 

  168. Brewster AM, Christo DK, Lai H, Helzlsouer K (2005) Breast carcinoma chemoprevention in the community setting: estimating risks and benefits. Cancer 103:1147–1153

    Article  PubMed  Google Scholar 

  169. Hirayama T (1979) Epidemiology of prostate cancer with special reference to the role of diet. Natl Cancer Inst Monogr Nov:149–155

    Google Scholar 

  170. Sporn MB (1996) The war on cancer. Lancet 347:1377–1381

    Article  CAS  PubMed  Google Scholar 

  171. Briel M, Nordmann AJ, Bucher HC (2005) Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and meta-analyses. Curr Opin Lipidol 16:601–605

    Article  CAS  PubMed  Google Scholar 

  172. Palmer ME, Haller C, McKinney PE, Klein-Schwartz W, Tschirgi A, Smolinske SC, Woolf A, Sprague BM, Ko R, Everson G, Nelson LS, Dodd-Butera T, Bartlett WD, Landzberg BR (2003) Adverse events associated with dietary supplements: an observational study. Lancet 361:101–106

    Article  PubMed  Google Scholar 

  173. Stephens NG, Parsons A, Scholfield PM, Kelly F, Cheeseman K, Mitchinson MJ (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge heart anti-oxidant study (CHAOS). Lancet 347:781–786

    Article  CAS  PubMed  Google Scholar 

  174. GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione Trial. Lancet 354:447–455

    Article  Google Scholar 

  175. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:140–146

    Google Scholar 

  176. Cook NR, Stampfer MJ, Ma J, Manson JE, Sacks FM, Buring JE, Hennekens CH (1999) Beta-carotene supplementation for patients with low baseline levels and decreased risks of prostate carcinoma and cancer overall. Cancer 86:1783–1792

    Article  CAS  PubMed  Google Scholar 

  177. Larkin M (1998) Controversy over diet to “prevent cancer”. Lancet 52:1789–1790

    Article  Google Scholar 

  178. Sonn GA, Aronson W, Litwin MS (2005) Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 8:304–310

    Article  CAS  PubMed  Google Scholar 

  179. Yan L, Spitznagel EL (2005) Meta-analysis of soy food and risk of prostatic cancer in men. Int J Cancer 117:667–669

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laurel Cottage, Castleton, Cardiff, CF3 2UR, UK

    Keith Griffiths DSc

  2. Department of Urology, University of Naples “Federico II”, Via S. Pansini 5, 80123, Naples, Italy

    Domenico Prezioso MD

  3. Department of Chemical Pathology, University Hospital of Wales, Heath Cardiff, UK

    A. Turkes PhD

  4. Lange Gasthuisstraat 35-37, 2000, Antwerp, Belgium

    Louis J. Denis MD, FACS (Director Oncology Centre Antwerp Secretary Europa Uomo)

Authors
  1. Keith Griffiths DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Domenico Prezioso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Turkes PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louis J. Denis MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, 52621, Israel

    Jacob Ramon MD

  2. Lange Gasthuisstraat 35-37, 2000, Antwerp, Belgium

    Louis J. Denis MD, FACS (Director Oncology Centre Antwerp Secretary Europa Uomo) (Director Oncology Centre Antwerp Secretary Europa Uomo)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Griffiths, K., Prezioso, D., Turkes, A., Denis, L.J. (2007). The Prevention of Prostate Cancer. In: Ramon, J., Denis, L.J. (eds) Prostate Cancer. Recent Results in Cancer Research, vol 175. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-40901-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-40901-4_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40897-0

  • Online ISBN: 978-3-540-40901-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation